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Abstract 22 
 23 
Intracellular availability of glucocorticoids is regulated by the enzymes 11β-24 
hydroxysteroid dehydrogenase 1 (11β-HSD1) and 11β-hydroxysteroid dehydrogenase 2 25 
(11β-HSD2). 11β-HSD1 activity is measured in urine by the (tetrahydrocortisol +5α-26 
tetrahydrocortisol)/tetrahydrocortisone ((THF+5α-THF)/THE)ratio  in humans, and 27 
(tetrahydrocorticosterone+5α-tetrahydrocorticosterone)/11-dehydrocorticosterone 28 
((THB+ 5α-THB)/THA) in mice. The cortisol/cortisone (F/E) ratio in humans and 29 
corticosterone/11-dehydrocorticosterone (B/A) in mice is a marker for 11β-HSD2 30 
activity. In vitro agonist treatment of LXR downregulates 11β-HSD1. 31 
Sterol 27-hydroxylase (CYP27A1) catalyses the first step in the alternative pathway of 32 
bile acid synthesis by hydroxylating cholesterol to 27-hydroxycholesterol (27-OHC). 33 
Since 27-OHC is a natural ligand for LXR, we hypothesized that CYP27A1 deficiency 34 
may upregulate 11β-HSD1. 35 
In a patient with cerebrotendinous xanthomatosis carrying a loss of function mutation in 36 
CYP27A1, 27-OHC plasma concentrations were dramatically reduced (3.8 ng/ml vs 90-37 
140 ng/ml in healthy controls) and the urinary ratios of (THF+5α-THF)/THE and F/E 38 
increased, demonstrating enhanced 11β-HSD1 and diminished 11β-HSD2 activities. 39 
Similarly, in cyp27A1 knockout (ko) mice, 27-OHC plasma concentrations were 40 
undetectable (<1 ng/ml versus 25-120 ng/ml in cyp27A1 wild type (wt) mice). Urinary 41 
ratios of (THB+5α-THB)/THA were 4-fold, and of B/A 2-fold, higher in cyp27A1 ko 42 
than in their wt littermates. The (THB+5α-THB)/THA ratio also increased significantly in 43 
plasma, liver and kidney of cyp27A1 ko mice. In the liver of these mice, the increase of 44 
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11β-HSD1 activity, and increased expression of protein and mRNA were due to 45 
increased liver weight as a consequence of cyp27A1 deficiency.  46 
Our studies suggest that CYP27A1 expression modulates active glucocorticoid 47 
concentration in both humans and mice.  48 
49 
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Introduction 50 
 51 
Sterol 27-hydroxylase (CYP27A1) encoded by the gene CYP27A1 is a NADPH-52 
dependent mitochondrial enzyme expressed in many tissues which catalyses the 53 
hydroxylation of cholesterol to 27-hydroxycholesterol (27-OHC) (Rosen, et al. 1998). In 54 
the liver, CYP27A1 catalyses the first step of the alternative pathway of bile acid 55 
biosynthesis and intermediate reactions in the classic pathway initiated by CYP7A1 56 
(Chen, et al. 2005). In extra-hepatic tissues, CYP27A1 plays a role in reverse cholesterol 57 
transport because its product 27-OHC  is removed and carried to the liver where it can 58 
be converted to bile acids (Weingartner, et al. 2010). 27-OHC is a key regulator of 59 
cholesterol homeostasis. It is one of the natural ligands for LXR, which upon activation, 60 
enhances the ABCA-1 mediated cholesterol efflux (Oram and Lawn 2001) and is a 61 
negative feedback regulator of HMG-CoA reductase, the rate-limiting enzyme for 62 
cholesterol biosynthesis (Hall, et al. 2001).  63 
In humans, the importance of CYP27A1 in sterol homeostasis is illustrated by 64 
cerebrotendinous xanthomatosis (CTX), an autosomal recessive disease caused by a loss 65 
of function mutation in the CYP27A1 gene (Cali, et al. 1991). Clinical features of CTX 66 
include early onset cataracts, progressive neurological dysfunction, tendon xanthomas 67 
and in some but not all patients, increased incidence of premature atherosclerosis (Cali 68 
et al. 1991). Cyp27A1 gene knockout (ko) mice have reduced bile acid elimination and 69 
pronounced hepatomegaly (Dubrac, et al. 2005; Honda, et al. 2001; Repa, et al. 2000). 70 
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In clinical practice, glucocorticoids are widely used as anti-inflammatory and 71 
immunosuppressive agents. They have a direct effect on the transcription regulation of 72 
CYP27A1 (Tang, et al. 2008). Intracellular glucocorticoid concentrations are modulated 73 
by the 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes. 11β-HSD type 1 (11β-74 
HSD1) preferentially catalyses the conversion of inactive 11-keto-glucocorticoids 75 
(cortisone or 11-dehydrocorticosterone) into active 11β-hydroxyglucocorticoids (cortisol 76 
or corticosterone) and by this mechanism modulates cell-specific glucocorticoid action 77 
(Agarwal, et al. 1989; Edwards, et al. 1988; Escher, et al. 1997). 11β-HSD type 2 (11β-78 
HSD2) inactivates endogenous cortisol into cortisone (Funder, et al. 1988). In 79 
mineralocorticoid target tissues, 11β-HSD2 protects mineralocorticoid receptors from 80 
excessive activation by glucocorticoids (Atanasov, et al. 2007; Mune, et al. 1995). 81 
Regulation of cortisol metabolism into tetrahydrometabolites in the liver is catalysed by 82 
the enzyme 5α-reductase (Russell and Wilson 1994). 83 
 84 
Recently, evidence has accumulated that 11β-HSD1 activity contributes to glucocorticoid 85 
effects in the development of the metabolic syndrome (Hermanowski-Vosatka, et al. 86 
2005). With the ultimate goal of treating and/or preventing the metabolic syndrome, an 87 
array of exogenous compounds inhibiting 11β-HSD1 has recently been synthesized 88 
(Boyle and Kowalski 2009), and the role of endogenous compounds including insulin, 89 
glucocorticoids, TNF-alpha, bile acids and their molecular mechanisms in regulating the 90 
expression and activity of 11β-HSD were reported (Ackermann, et al. 1999; 91 
Balachandran, et al. 2008; Escher et al. 1997; Ignatova, et al. 2009; Kostadinova, et al. 92 
2005; Quattropani, et al. 2001; Williams, et al. 2000). Thus, understanding the factors 93 
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regulating activity of this enzyme is of potential clinical importance. Interestingly, 94 
glucocorticoids themselves regulate CYP27A1 (Tang et al. 2008). 95 
The LXR family of nuclear receptors (LXRs) are ligand-activated transcription factors 96 
playing roles in regulation of bile acid synthesis and metabolism, macrophage 97 
cholesterol efflux and lipid metabolism (Lehmann, et al. 1997; Peet, et al. 1998; 98 
Schwartz, et al. 2000). A role for LXRs in endocrine regulation was proposed by Stulnig 99 
(Stulnig, et al. 2002) who showed that activation of LXRs by the agonist TO901317 100 
down-regulates 11β-HSD1 expression and activity in adipocytes, an observation 101 
confirmed in hepatocytes (Liu, et al. 2006).  102 
Based on the interplay described between LXR and 11β-HSD1 and between 27-OHC 103 
and LXR, we asked whether glucocorticoid homeostasis might differ in CTX patients so 104 
that 11β-HSD1 activity, estimated by urinary glucocorticoid metabolites, may be 105 
increased as compared to healthy controls. To further investigate involvement of 106 
CYP27A1 in glucocorticoid metabolism, we analysed plasma, urine and tissues of 107 
cyp27A1 gene KO mice in which 27-OHC is deficient (Dubrac et al. 2005; Rosen et al. 108 
1998).   109 
110 
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Materials and methods 111 
  112 
Ethics Statement 113 
The results given for the CTX patient are parameters commonly used in  routine diagnosis 114 
in our institution. The agreement in the University Hospital stipulates that results may be 115 
used anonymously for scientific purposes. 116 
Animal experimentation was approved by the Ethical Committee for Animal Experiments 117 
of the Veterinary Administration of the Canton of Berne, Switzerland. 118 
 119 
Case Report 120 
The phenotype of the CTX patient has been described previously (Bartholdi, et al. 2004). 121 
Neurologically, she had progressive spastic tetraparesis and neurocognitive problems. No 122 
tendon xanthomas were found but she reported chronic diarrhea. A 24h urine sample and 123 
10 ml blood collected in EDTA tubes were obtained and levels of 27-OHC and urinary 124 
steroid metabolites measured.  125 
 126 
Mouse colonies 127 
Cyp27A1 heterozygous males and females (a kind gift from Sandra K Erickson, 128 
Department of Medicine, University of California, San Francisco, USA) on a C57BL/6J 129 
genetic background were used to breed cyp27A1 wild type (WT), heterozygous (HZ) and 130 
knockout (KO) mice. Pups were genotyped at 3 weeks (for primers and PCR conditions, 131 
see (Dubrac et al. 2005) and weaned at the age of 4 weeks. Males used for the experiment 132 
were maintained on standard rodent chow. Urine was collected from 4 to 6 month old 133 
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animals as follows. Mice were housed separately for one week, placed for pre-adaptation 134 
in a metabolic cage for 3 days and urine collected every 24h for the next 3 days. At the 135 
end of the collection, mice were starved for 12 hours, sacrificed by pentobarbital injection 136 
(300 mg/kg, pentobarbital sodium, USP, Abbott Laboratories North Chicago, IL60064, 137 
USA), weighed and blood collected into a tube containing 20-50 units heparin. Plasma 138 
was centrifuged and stored at –20°C until use. Organs were removed, weighed, frozen in 139 
liquid nitrogen and stored at -80°C until use.  140 
 141 
Plasma and liver biochemistry  142 
Glucose, cholesterol, triglycerides, ALT and AST were measured by 143 
electrochemiluminescence immunoassay (Roche Diagnostics, Switzerland). Insulin was 144 
measured with the ultra sensitive rat/mouse insulin Elisa kit (Crystal Chem Inc (Cat No 145 
90060), Downers Grove, IL, USA). 27-OHC was quantified by GC-MS as previously 146 
described (Burkard, et al. 2004) with 100 ng 5α-cholestan-3β,6α-diol and 100 ng 147 
stigmasterol as standards; for details, see supplementary material. 148 
Triglyceride content was measured in liver homogenates with a triglyceride 149 
Quantification Kit (BioVision (Cat No K622-100), Mountain View, CA, USA).  150 
 151 
Analysis of steroid metabolites by gas chromatography-mass spectrometry 152 
For both mouse and human samples, urinary steroids were extracted from 1.5 ml urine 153 
and analysed by GC-MS as previously described (Ackermann et al. 1999; Escher, et al. 154 
2009; Odermatt, et al. 2001). In human urine, tetrahydrocortisol (THF), 5α-155 
tetrahydrocortisol (5α-THF), tetrahydrocortisone (THE), cortisol (F), cortisone (E), α-156 
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cortol, β-cortol, α-cortolone, β-cortolone were quantified. In mouse urine 157 
tetrahydrocorticosterone (THB), 5α-tetrahydrocorticosterone (5α-THB), 11-dehydro-158 
tetrahydrocorticosterone (THA), corticosterone (B) and dehydrocorticosterone (A) were 159 
measured. Glucocorticoid metabolites were also quantified in plasma (100-400 µl), liver 160 
and kidney tissues (100 mg). Following an extraction step with10  vol dichloromethane, 161 
steroids were extracted in the organic phase and derivatized. The detection limit was 1 162 
ng/ml for plasma or urine and 1 ng/100 mg for tissue. 163 
 164 
Enzymatic assays 165 
11β-HSD1 activity in mouse liver homogenates 166 
Reduction of cortisone to cortisol was used to assess 11β-HSD1 activity. Frozen liver 167 
samples were powdered and 30-50 mg tissue homogenized with 500 µl buffer containing 168 
250 mM sucrose, 10 mM Tris Base pH 7.5 and 1 mM PMSF. Protein was quantified with 169 
a BCATM Protein Assay Kit (Pierce Cat No 23225, Rockford, IL 61105, USA). For 11β-170 
HSD1 assay, 10 µg protein was incubated for 30 min at 37°C in the presence of 951 mol/l 171 
β-nicotinamide adenine dinucleotide 2’-phosphate reduced tetrasodium salt (NADPH), 172 
1.5 µmol/l cortisone and 3.2 nCi of [3H]-cortisone in sucrose buffer. The reaction was 173 
stopped by adding 30 µl of a mixture containing 10 mg/ml cortisone and cortisol in 174 
methanol. Samples were spotted onto TLC plates ((G-25, UV254) Macherey-Nagel, 175 
Oensingen, Switzerland) and developed in a solvent containing chloroform-methanol 176 
(90:10 v/v). Steroids were visualized under ultraviolet light, the spots removed and 177 
counted in a Packard scintillation counter (Tri-Carb 2000CA; United Technologies, 178 
Hartford, CT, USA), and the percentage of conversion of cortisone to cortisol calculated.  179 
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11β-HSD2 activity in kidney homogenates 180 
11β-HSD2 activity was assessed by measuring oxidation of corticosterone to 181 
dehydrocorticosterone. Kidney homogenates were prepared as described above for liver 182 
from 30-50 mg of frozen tissue. Assay of 11β-HSD2 activity was performed using 10 µg 183 
protein and incubated for 90 min at 37°C in a mixture containing 200 mol/l nicotinamide 184 
adenine dinucleotide (NAD), 10 nmol/l corticosterone and 3.2 nCi of [3H]-corticosterone 185 
in sucrose buffer. The reaction was stopped by adding 30 µl of a mixture containing 10 186 
mg/ml corticosterone and dehydrocorticosterone in methanol. TLC was performed as 187 
described above and the percentage of conversion of corticosterone to 188 
dehydrocorticosterone calculated. 189 
 190 
RNA extraction and real-time PCR 191 
Total RNA was isolated from frozen tissues with a SV Total RNA Isolation System Kit 192 
(Promega Cat No Z3100, Madison, WI, USA). Reverse transcription was performed with 193 
2 µg RNA in a reaction containing 100 Units SuperScript Reverse Transcriptase type II 194 
according to the manufacturer’s protocol (Invitrogen  Cat No 18064-022). Real-time PCR 195 
was performed with specific TaqMan Gene Expression Assays and 18S or β-actin as the 196 
housekeeping gene, using ABI Prism 7500 Fast Sequence Detection System (version 197 
1.4). 198 
 199 
Western Blot analysis 200 
20 μg of liver homogenates was separated on a 12.5% SDS polyacrylamide gel by 201 
electrophoresis, followed by immunoblotting with anti-11β-HSD1 rabbit antiserum (kind 202 
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gift from C. Monder) at a dilution of 1:1’000 in 2% non-fat dried milk. Bands were 203 
visualized with an Enhanced Chemiluminescence kit (Amersham Cat No RPN2106) and 204 
quantified by densitometry using Image J. For internal standard, β-actin (Santa-Cruz) was 205 
used at a dilution of 1:3’000 in 2% non-fat dried milk.  206 
 207 
Effect of 27-OHC on 11β-HSD1 activity in vitro 208 
For dose-dependent inhibition studies, CHOP cells were transfected as described 209 
previously (Escher et al. 2009) with a plasmid encoding 11β-HSD1. Two days following 210 
transfection, cells were harvested, homogenized in sucrose buffer (100 mM sucrose, 10 211 
mM Tris pH 7.4) and enzymatic assays and TLC were performed as described above in 212 
the presence of  increasing concentration of 27-OHC diluted in ethanol. 213 
To measure the direct effect of CYP27A1 expression on 11β-HSD1 activity, CHOP cells 214 
were co-transfected with 2 plasmids, one encoding 11β-HSD1 and the other CYP27A1 or 215 
pcDNA3. Enzymatic assay was performed for 4h at 37°C and protein  amount  was 216 
determined to calculate the specific activity. 217 
 218 
Statistical analysis 219 
To determine significant differences, one-way ANOVA was used, followed by 220 
Bonferroni post-hoc tests for multiple comparisons or Kruskal-Wallis followed by Dunn's 221 
multiple comparison tests.  222 
223 
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Results 224 
 225 
Analysis of  27-OHC and glucocorticoid metabolites in the patient with CTX  226 
The concentration of 27-OHC in plasma from the CTX patient was reduced (3.8 ng/ml 227 
versus 90-140 ng/ml normal range in controls) (Burkard et al. 2004), reflecting decreased 228 
sterol 27-hydroxylase activity (Table 1). To establish whether this decreased 229 
concentration of 27-OHC was mirrored by changes in glucocorticoid ratios reflecting 230 
11β-HSD1 activity, metabolites of glucocorticoids were determined in plasma and urine 231 
by GC-MS. In plasma, F was in the normal range when compared to controls obtained 232 
from a previous study (N'Gankam, et al. 2002) but no E was detected (Table 1). In urine, 233 
increased (THF+5α-THF)/THE and cortols/cortolones, indicating increased reductive 234 
activity of 11β-HSD1, and an increased F/E ratio reflecting diminished oxidative activity 235 
of 11β-HSD2 were observed. The ratio THF/5α-THF, a measure of 5α-reductase activity, 236 
remained unchanged (Table 1). 237 
 238 
Phenotype changes in cyp27A1 deficient mice 239 
Body weight remained unchanged but liver size was almost twice as large in cyp27A1 ko 240 
mice as in wt or hz mice (Table 2). Kidneys, spleen, lungs, testis and brain weight were 241 
unchanged (data not shown). Plasma 27-OHC was undetectable in cyp27A1 ko mice but 242 
not significantly reduced in cyp27A1 hz mice (Table 2). CYP27A1 deficiency led to an 243 
increase of plasma ALT and AST plus a decrease of cholesterol, a lower glucose and 244 
higher insulin whereas plasma triglyceride levels were unchanged (Table 2) despite 245 
accumulation of triglycerides in cyp27A1 ko livers (Table 2). 246 
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 247 
 248 
Analysis of glucocorticoid metabolites in cyp27A1 ko mice  249 
11β-HSD1 reductive activity assessed from the ratio (THB+5α-THB)/THA increased 4-250 
fold in urines of cyp27A1 ko mice compared with wt or hz mice (Fig. 1A). The B/A ratio 251 
ratio increased more than 2 fold, indicating an apparent decrease of 11β-HSD2 oxidative 252 
activity (Fig. 1B). The THB/5α-THB ratio, a marker for 5α- reductase activity, was 253 
markedly reduced in cyp27A1 ko mice, indicating enhanced A-ring reduction of THB 254 
(Fig. 1C). The total amount of steroids excreted in 24h was unchanged (data not shown) 255 
and the (THB+5α-THB)/THA ratio correlated positively with liver size (Fig. 1D). The 256 
(THB+5α-THB)/THA ratio was also significantly increased in plasma, liver and kidney 257 
of cyp27A1 ko mice (Fig 2A, C and D) with no changes observed in adrenals (data not 258 
shown). The B/A ratio also increased in plasma of cyp27A1 ko mice (Fig. 2B) and 259 
similarly was unchanged in adrenals (data not shown). Both B and A were below the 260 
detection limit in liver and kidney tissue. 261 
 262 
Assessment of 11β-HSD1 activity, protein and mRNA levels in mouse livers and 263 
kidneys 264 
11β-HSD1 activity was measured in liver homogenates, with levels of both shown to be 265 
independent of CYP27A1 genotype (Fig. 3A and 3B). 11β-HSD1 protein content was 266 
quantified by Western Blot in liver homogenates, with β-actin as internal control (Fig. 267 
3C). The amount of 11β-HSD1 protein correlated with liver size (Fig. 3D). 268 
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In liver tissue, 11β-HSD1 mRNA levels were similar across all 3 genotypes (Fig. 4A). 269 
The mRNA level of hexose-6-phosphate dehydrogenase (H6PDH), a known modulator of 270 
11β-HSD1 activity (Bujalska, et al. 2005; Walker, et al. 2007), was similarly unchanged 271 
(Fig. 4B), as were 11β-HSD1and 11β-HSD2 mRNA in kidney tissue from all 3 genotypes 272 
(Fig. 4C and 4D).  273 
 274 
Inhibition of 11β-HSD1 by 27-OHC in vitro 275 
The effect of 27-OHC on 11β-HSD1 activity was assessed in vitro in a lysate of CHOP cells 276 
transfected with a plasmid encoding 11β-HSD1.27-OHC inhibited 11β-HSD1 in a  dose-277 
dependent manner (Fig. 5A). Similarly, 11β-HSD1 specific activity was significantly reduced in 278 
CHOP cells transfected with 11β-HSD1 when CYP27A1 was expressed (Fig. 5B). 279 
 280 
281 
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Discussion 282 
 283 
Regulation of 11β-HSD1 and 11β-HSD2 enzymes by different endogenous molecules 284 
and xenobiotics and in various disease states has been previously described and appears 285 
to be clinically relevant (Escher et al. 1997; Escher, et al. 1998a; Escher, et al. 1998b; 286 
Fuster, et al. 1998; Heiniger, et al. 2003; Ignatova et al. 2009; Konopelska, et al. 2009; 287 
Kostadinova et al. 2005; Quattropani et al. 2001). Here we add a novel player, 27-OHC, 288 
regulating the activity of these key enzymes determining intracellular glucocorticoid 289 
availability. As a confirmation of our hypothesis, and schematised in Fig. 6, we showed a 290 
diminished production of 27-OHC in the CTX patient, and diminished 27-OHC enhanced 291 
LXR-driven inhibition of 11β-HSD1. As a result, the conversion of inactive to active 292 
glucocorticoids increased reflecting increased activity of 11β-HSD1, as shown by the 293 
absence of E in plasma and elevated urinary (THF+5α-THF)/THE and cortol/cortolone 294 
ratios. Combined with an increased F/E ratio, an apparent indicator of reduced 11β-HSD2 295 
activity, an overall increase of active glucocorticoids was found in the urine of the CTX 296 
patient analysed. 297 
Similarly, in the absence of circulating 27-OHC, cyp27A1 ko mice have an increased 298 
(THB+5α-THB)/THA ratio in urine but also in plasma, liver and kidney. With an 299 
increased B/A ratio in plasma and urine, cyp27A1 ko mice tissues are clearly exposed to 300 
increased levels of active glucocorticoids.  301 
In vitro, 27-OHC inhibited 11β –HSD1 activity in a dose-dependent manner, and over-302 
expression of CYP27A1 led to reduced 11β-HSD1 activity (Fig. 5). Thus 27-OHC itself 303 
acts as inhibitor on11β-HSD1 (Fig. 6).  304 
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Similar changes observed in the steroid ratios occur as a consequence of a reduced bile 305 
acid production (Cali et al. 1991; Dubrac et al. 2005; Peet et al. 1998; Rosen et al. 1998). 306 
It has been shown that removal of a biliary obstruction in patients with cholestasis with a 307 
subsequent decrease in the concentrations of bile acids in plasma had similar impacts on 308 
the urinary ratios of (THF + 5αTHF)/THE (Quattropani et al. 2001). CTX patients 309 
including the present patient are classically treated with chenodeoxycholic acid (CDCA), 310 
a substance known to inhibit 11β-HSD1 and 11β-HSD2 (Ackermann et al. 1999). This 311 
treatment could explain the different level of increase in the urinary ratio between the 312 
CTX patient and the cyp27A1 ko mice. Without treatment with bile acids, cyp27A1 ko 313 
mice had a 4 fold increase in the (THB+5α-THB)/THA ratio, whereas (THF+5α-314 
THF)/THE was only modestly increased in our patient who received CDCA. 315 
Besides 11β-HSD1 activity, the total levels of glucocorticoids excreted and the enzyme 316 
5α-reductase are also important determinants of the F/E and (THF+5α-THF)/THE ratios.  317 
In this study, the amount of steroids excreted in urine was in the same range for the 3 318 
groups of mice, and in the CTX patient within control values (data not shown). By 319 
contrast, 5α-reductase activity was unchanged in the CTX patient but decreased in 320 
cyp27A1 ko mice (Table 1 & Fig. 1C), a finding that may reflect a difference between 321 
humans  and mice as to the phenotypic expression of CYP27A1 depletion, i.e. hepatic 322 
steatosis in cyp27A1 ko mice and its absence in the CTX patient. A recent study (Ahmed, 323 
et al. 2012) showed an increased 5α-THF/THF ratio in patients with steatosis compared 324 
to controls, a finding in line with the reduction of THB/5α-THB in cyp27A1 ko mice.  325 
The role of endogenous glucocorticoids in the pathogenesis of the metabolic syndrome 326 
and individuals suffering from the Cushing’s syndrome is well established, as well as 327 
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their involvement in hepatic triglyceride accumulation (Dourakis, et al. 2002). In non-328 
alcoholic fatty liver disease, one of the manifestations of the metabolic syndrome, 329 
increased clearance and decreased hepatic regeneration of cortisol has been proposed as a 330 
protective mechanism to decrease local glucocorticoid availability (Ahmed et al. 2012). 331 
The clinical implication of the increased glucocorticoid availability in our CTX could be 332 
of interest. Given the glucocorticoid responsive element in the promoter sequence of 333 
CYP27A1, increased cortisol concentration might contribute substantially to CYP27A1 334 
residual activity. Even more, this could explain the different susceptibility of CTX to 335 
develop or not atherosclerosis. 336 
In the present study, we found that cyp27A1 ko mice have increased circulating and tissue 337 
glucocorticoid levels (Fig. 2A) that could, at least in part, explain their hepatomegaly.  338 
Taken together, our results indicate that the reduction of 27-OHC production by 339 
CYP27A1 and its effect on 11β-HSD1 activity enhances tissue glucocorticoid 340 
concentration and could, at least in part, lead to the development of steatosis. 341 
Administration of 27-OHC to LDL-receptor ko mice has been shown to reduce the 342 
accumulation of lysosomal cholesterol and hepatic inflammation in the liver (Bieghs, et 343 
al. 2013). If reduced 27-OHC concentrations are found in the circulation of patients with 344 
fatty liver, enhancing CYP27A1 activity might then be a viable therapeutic option. 345 
The changes in glucocorticoid ratios observed in cyp27A1 ko mice were not regulated at 346 
the level of 11β-HSD1 mRNA or protein in the liver (Fig. 3C & 4), and the specific 347 
activities of 11β-HSD1 and 11β-HS2 were similarly not changed (Fig. 3A &B). Thus, we 348 
might speculate that the increased (THB+5α-THB)/THA ratio observed in urine, plasma 349 
and liver are solely due to (i) increased liver mass, (ii) increased hepatic capacity to 350 
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regenerate active glucocorticoids via 11β-HSD1, (iii) decreased bile acid production, (iv) 351 
cofactor availability, and/or  (v) to direct or indirect inhibition of 11β-HSD1 via 352 
activation of LXR by 27-OHC. 353 
In conclusion, we show that reduced CYP27A1 activity enhances active glucocorticoid 354 
levels in humans and mice. It is the first evidence that not only xenobiotics but enzymatic 355 
activity are involved in the regulation of 11β-HSD1. In addition, hepatomegaly and 356 
hepatic steatosis in cyp27A1 ko mice may also be a consequence of increased 357 
glucocorticoid availability. 358 
359 
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Figure legends 520 
 521 
Figure 1. Effect of CYP27A1 deficiency on the excretion of urinary glucocorticoid 522 
metabolites in mice.  523 
Steroids were extracted from cyp27A1 wt, hz and ko mice urines and analysed by GC-524 
MS. The (THB+5α-THB)/THA ratio increased ~4 fold in cyp27A1 ko mice compared to 525 
wt, indicating an increased apparent 11β-HSD1 reductive activity (A). The B/A ratio (B) 526 
doubled in cyp27A1 ko mice, indicating reduced apparent 11β-HSD2 oxidase activity. 527 
The THB/5α-THB ratio, a measurement of liver 5α-reductase, fell ~ 6 fold in cyp27A1 ko 528 
mice (C). There was a correlation between the (THB+5α-THB)/THA ratio and liver size 529 
(p= 0.0003) (circles represent cyp27A1 wt, squares cyp27A1 hz and triangles cyp27A1 ko 530 
mice) (D). Mouse urine sample number  : n=9, 7, 6 for cyp27A1 wt, hz and ko mice, 531 
respectively. Means with whiskers (minimum and maximum) are represented. One-way 532 
ANOVA followed by Bonferroni post-hoc tests for multiple comparisons were used to 533 
test statistical differences, with *** p<0.0001 and ** p<0.001for cyp27A1 ko versus wt 534 
mice. 535 
 536 
Figure 2. Effect of CYP27A1 deficiency on plasma and tissue glucocorticoid 537 
metabolites in mice. 538 
Steroids were extracted from plasma, liver and kidney and analysed by GC-MS. The 539 
(THB+5α-THB)/THA and B/A ratios increased by ~50% in plasma (A and B). The ratio 540 
(THB+5α-THB)/THA increased by less than 50% in liver (C) and kidney (D) 541 
homogenates. Number of mouse samples: n=5; means with whiskers (minimum and 542 
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maximum) are represented. One-way ANOVA followed by Bonferroni post-hoc tests for 543 
multiple comparisons or Kruskal-Wallist tests followed by Dunn tests were used to test 544 
statistical differences, with *** p<0.0001 and ** p<0.001 for cyp27A1 ko versus wt mice. 545 
 546 
Figure 3. Effect of CYP27A1 deficiency on 11β-HSD1 and 11β-HSD2 activity in 547 
mouse liver and kidney and 11β-HSD1 protein in liver. 548 
Activity was assayed in liver (11β-HSD1) (A) and kidney (11β-HSD2) (B) homogenates 549 
from cyp27A1 wt, hz and ko mice and expressed as percentage of conversion of substrate 550 
to product. No difference between the 3 groups of animals was seen. 11β-HSD1 protein 551 
was quantified in liver homogenates by Western Blot, with β-actin as internal standard. A 552 
representative blot is shown (C) with lane 1, cyp27A1 wt; lane 2, cyp27A1 hz; lane 3, 553 
cyp27A1 ko. The relative amount of 11β-HSD1 protein increased with liver size 554 
(p=0.0387) (D). Number of samples: n=8, 10 and 7 for cyp27A1 wt, hz and ko mice, 555 
respectively, and values are represented as means and whiskers (minimum and 556 
maximum). Circles represent cyp27A1 wt, squares cyp27A1 hz and triangles cyp27A1 ko 557 
mice. 558 
  559 
Figure 4. Quantification of hepatic and renal 11β-HSD1, 11β-HSD2 and H6PD 560 
mRNA.  561 
In liver, there was no change of 11β-HSD1 (A) and H6PDH (B) mRNA in cyp27A1 ko 562 
mice as compared to cyp27A1 wt littermates; there was similarly no change in 11β-HSD2 563 
(C) or 11β-HSD1 (D) mRNA in kidney. Values are represented as means with whiskers 564 
(minimum and maximum); n=7, 13 and 10 for cyp27A1 wt, hz and ko mice, respectively. 565 
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Figure 5. Effect of CYP27A1 expression on 11β-HSD1 activity in vitro. 566 
CHOP cells were transfected as described in the method section. (A) 27-OHC inhibited 11β-567 
HSD1activity in a dose dependently. (B) Specific activity was reduced in CHOP cells 568 
overexpressing 11β-HSD1 and transfected with CYP27A1 when compared to those transfected 569 
with p.  The figures are representative experiments performed in triplicates. Values are mean ± 570 
SD. 571 
 572 
Figure 6. Tissue specific interplay between CYP27A1 and glucocorticoid 573 
metabolism.  574 
Cortisol (F), cortisone (E) and their corresponding metabolites 5α-tetrahydrocortisol (5α-575 
THF), 5β-tetrahydrocortisol (THF) and tetraydrocortisone (THE), and in addition cortols 576 
and cortolones can be quantified in urine and used as markers for local regulation of 11β-577 
HSD1 and 11β-HSD2 enzyme activity. In liver, conversion of cortisone to cortisol by 578 
11β-HSD1 is inhibited by both 27-OHC and bile acids. 27-OHC inhibits 11β-HSD1 579 
indirectly via LXR (Stulnig et al. 2002) and directly (Fig. 5). Thus, reduced CYP27A1 580 
activity causes an increased activity of 11β-HSD1, an overall effect favouring the 581 
formation of cortisol and its metabolites. Furthermore, the formation of cortisol in tissues 582 
expressing 11β-HSD2, mainly the kidney, is enhanced since bile acids inhibit 11β-HSD2 583 
activity, i.e. the conversion of cortisol into cortisone. Thus, overall absence of CYP27A1 584 
favours the formation of cortisol and its metabolites. 585 
 586 
587 
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